This took the form of a nearly 5-million strong, secondary share issue. Nektar Therapeutics (NASDAQ:...
Nektar Therapeutics (NKTR) slid 4.5% on Thursday after the biopharmaceuticals firm overnight said it...
Plus, news about BrainEver, Clinigen, MaaT Pharma, Dyadic and Nektar Therapeutics: Cloudbreak Pharma...
SAN FRANCISCO, July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage bio...